| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 273 | 2022 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti*, X Wang*, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 231 | 2022 |
| Association between smoking history and tumor mutation burden in advanced non–small cell lung cancer X Wang, B Ricciuti, T Nguyen, X Li, MS Rabin, MM Awad, X Lin, ... Cancer research 81 (9), 2566-2573, 2021 | 119 | 2021 |
| Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC JV Alessi*, A Elkrief*, B Ricciuti*, X Wang, A Cortellini, VR Vaz, ... Journal of Thoracic Oncology 18 (6), 731-743, 2023 | 61 | 2023 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 59 | 2022 |
| Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer X Wang, B Ricciuti, JV Alessi, T Nguyen, MM Awad, X Lin, BE Johnson, ... JNCI: Journal of the National Cancer Institute 113 (12), 1761-1769, 2021 | 46 | 2021 |
| Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multicancer biomarker MS Taylor, C Wu, PC Fridy, SJ Zhang, Y Senussi, JC Wolters, T Cajuso, ... Cancer discovery 13 (12), 2532-2547, 2023 | 42 | 2023 |
| Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer B Ricciuti, G Lamberti, SR Puchala, NR Mahadevan, JR Lin, JV Alessi, ... Journal of Clinical Oncology 42 (11), 1311-1321, 2024 | 38 | 2024 |
| Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer B Ricciuti, J Son, JJ Okoro, A Mira, E Patrucco, Y Eum, X Wang, R Paranal, ... Clinical Cancer Research 28 (8), 1640-1650, 2022 | 36 | 2022 |
| Prediagnosis smoking cessation and overall survival among patients with non–small cell lung cancer X Wang, CW Romero-Gutierrez, J Kothari, A Shafer, Y Li, DC Christiani JAMA network open 6 (5), e2311966-e2311966, 2023 | 23 | 2023 |
| Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. JV Alessi*, X Wang*, A Elkrief, B Ricciuti, YY Li, H Gupta, LF Spurr, ... Journal of Thoracic Oncology, 2023 | 18 | 2023 |
| Immune Infiltration in Tumor and adjacent non-neoplastic regions codetermines Patient Clinical outcomes in Early-Stage Lung Cancer C Cheng, TT Nguyen, M Tang, X Wang, C Jiang, Y Liu, I Gorlov, ... Journal of Thoracic Oncology 18 (9), 1184-1198, 2023 | 14 | 2023 |
| Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC JV Alessi, B Ricciuti, X Wang, F Pecci, A Di Federico, G Lamberti, A Elkrief, ... Nature Communications 14 (1), 4238, 2023 | 13 | 2023 |
| RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade MJ Nokin, A Mira, E Patrucco, B Ricciuti, S Cousin, I Soubeyran, ... Nature communications 15 (1), 7554, 2024 | 10 | 2024 |
| Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥ 90%) Programmed Death-Ligand 1 Expression Treated … B Ricciuti, A Elkrief, J Lin, J Zhang, JV Alessi, G Lamberti, M Gandhi, ... JTO Clinical and Research Reports 5 (9), 100675, 2024 | 10* | 2024 |
| Use of machine learning to assess the prognostic utility of radiomic features for in-hospital COVID-19 mortality Y Sun, S Salerno, X He, Z Pan, E Yang, C Sujimongkol, J Song, X Wang, ... Scientific Reports 13 (1), 7318, 2023 | 9 | 2023 |
| Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors F Pecci, S Nakazawa, B Ricciuti, G Harada, JK Lee, JV Alessi, ... Cancer discovery 14 (8), 1440-1456, 2024 | 8 | 2024 |
| Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer A Di Federico, SL Alden, JW Smithy, B Ricciuti, JV Alessi, X Wang, ... Annals of Oncology 35 (10), 902-913, 2024 | 7 | 2024 |
| Tumor mutational burden for the prediction of PD-(L) 1 blockade efficacy in cancer: challenges and opportunities X Wang, G Lamberti, A Di Federico, J Alessi, R Ferrara, ML Sholl, ... Annals of Oncology 35 (6), 508-522, 2024 | 7 | 2024 |
| Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer B Ricciuti, A Elkrief, J Alessi, X Wang, Y Li, H Gupta, DM Muldoon, ... Clinical Cancer Research 29 (13), 2540-2550, 2023 | 7 | 2023 |
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer InstituteE-mailová adresa ověřena na: dfci.harvard.edu